DTIC vs. IFN-α plus DTIC in the treatment of patients with metastatic malignant melanoma

Neoplasma

Volumn 43, Issue 2, 1996, Pages 93-97

  Rudolf, Z ^a   Strojan, P ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

chemotherapy; interferon alpha; melanoma therapy; metastases

Indexed keywords

ALPHA INTERFERON; DACARBAZINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS;

EID: 0030009129     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. BALCH, C.M., HOUGHTON, A.N., PETERS, L.J.: Cutaneous melanoma. In: Cancer Principles and Practice of Oncology, Vol. 2. Eds: De Vita, V.T. Jr., Hellman, S., Rosenberg, S.A. Philadelphia, Lippincott Co. 1993, 1612-1661.
2. BAJETTA, E., DILEO, A., ZAMPINO et al.: Multicenter randomized trial of dacarbazine alone in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J. Clin. Oncol., 12, 1994, 806-811.
3. COATES, A.S.: Systemic chemotherapy for malignant melanoma. World J. Surg., 16, 1992, 277-281.
4. FALKSON, C.I., FALKSON, G., FALKSON, H.C.: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J. Clin. Oncol., 9, 1991, 1403-1408.
5. KAPLAN, E.L., MEIER, P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 1958, 457-481.
6. KIRKWOOD, J.M.: Studies of interferons in the therapy of melanoma. Semin. Oncol., 18, 1991, 83-90.
7. KLEEBERG, U.R., RUMKE, P., KIRKWOOD, J.M.: Systemic chemotherapy of advanced melanoma. Pigm. Cell., 10, 1990, 91-104.
8. PETO, R., PIKE, M.C., ARMITAGE, P. et al.: Design and analysis of randomised clinical trials requiring prolonged observation of each patients. II. Analysis and examples. Br. J. Cancer., 35, 1977, 1-39.
9. SERTOLI, M.R., QUEIROLO, P., BAJETTA, E. et al.: Dacarbasine (DTIC) with or without recombinant interferon alpha-2a at different dosage in the treatment of Stage IV melanoma patients. Preliminary results of a randomised trial. Proc. Am. Clin. Oncol., 11, 1992, 345.
10. THOMSON, D., ADENA, M., MCLEOD, G.R.C. et al.: Interferon α-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of multi-institutional Australian randomised trial QMP8704. Proc. Am. Soc. Clin. Oncol., 11, 1992, 343.